Join
Live feed
·
PRReleasevia Quantisnow
Praxis Precision Medicines Inc. logo

Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies

ByQuantisnow·Wall Street's wire, on your screen.
PRAX· Praxis Precision Medicines Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PRAX (Praxis Precision Medicines Inc.) and more on Quantisnow.